Autophagy Inhibition Using Hydrochloroquine in Breast Cancer Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01292408|
Recruitment Status : Unknown
Verified January 2012 by Radboud University.
Recruitment status was: Recruiting
First Posted : February 9, 2011
Last Update Posted : January 20, 2012
Hydroxychloroquine is a drug that has been used to treat malaria and rheumatism. It is recently discovered that Hydroxychloroquine increases 'autophagy'. Autophagy is a process whereby cells eat a part themselves giving them extra energy. Cancer cells use autophagy to survive chemotherapy or hormonal therapy. Also, cancer cells use autophagy to survive in areas of a tumor where there is a low oxygen level.
The purpose of this study is to determine whether treatment with the drug Hydroxychloroquine leads to a decrease of autophagy in breast cancer tissue.
|Condition or disease||Intervention/treatment||Phase|
|Breast Cancer||Drug: Hydrochloroquine||Phase 2|
In response to various stresses, cells can launch a process of "self-eating", termed autophagy. Thereby, components of the cell are catabolically digested via specific lysosomes called autophagosomes, to provide the cell with energy and other necessary factors to serve as a temporary survival mechanism (Chen et al. 2010).
Two major stressors that can be evaded by autophagy are important for cancer progression and treatment sensitivity:
- cells can respond with autophagy to cytotoxic treatment such as chemo- or endocrine therapy, thereby leading to treatment insensitivity (Kondo et al. 2005; Chen et al. 2010), and
- cells can survive severe hypoxia using autophagy (Rouschop et al. 2010), and hypoxic cells themselves are refractory to chemo-, endocrine and radiotherapy.
Thus, tumor cells evade treatment induced cell death by launching a temporary last survival mechanism. Inhibition of this pathway could lead to sensitization for a variety of cancer treatment regimen, or to specific cell killing of tumor associated hypoxic cells that would otherwise be refractory to radiotherapy. Chloroquine (CQ), N'-(7-chloroquinoline-4-yl)-N,N-diethyl-pentane-1,4-diamine, was discovered in 1934, and has widely been used as an effective and safe anti-malarial and anti-rheumatoid agent since 1947. Later, CQ has been rediscovered as a sensitizer of cytotoxic cancer therapies such as ionizing radiation and chemotherapeutics, although the precise mechanism behind this has remained largely unknown (Solomon and Lee 2009). Most recently, it was discovered that CQ inhibits the process of autophagy by impairment of autophagic vesicle clearance, as CQ accumulates in lysosomal vesicles. This has now lead to several investigators proposing that CQ or one of its analogs can be used to inhibit the autophagic pathway as an additive to other cytotoxic treatments. Hydrochloroquine (HCQ, Plaquenil) is a CQ derivative with fewer side effects than CQ, which has long been used as anti-malarial and antirheumatoid agent. It can be safely used at high doses for extended periods of time. Both CQ and HCQ are under investigation in clinical trials for glioblastoma, small and non-small cell lung cancer, breast cancer, prostate cancer, melanoma, renal cell carcinoma, and pancreatic cancer (for reviews see Solomon and Lee 2009 and Chen et al. 2010).
However, the effect of HCQ on tumor tissue, autophagy and/or oxygenation has of yet not been studied in human patients in vivo.
In this pilot study we intend to investigate the effect of HCQ on breast cancer tissues. To this end, breast cancer patients that have given informed consent for participation in the AFTER study (AMO 2010/312), but are not included as their tissue biopsy is found to be ER/PgR negative, will be asked to take 800 mg once, and then 400 mg/day HCQ for 2 to 3 weeks until surgery. We will compare tissue characteristics before and after treatment using HCQ, looking at effects on markers for both hypoxia and autophagy using immunohistochemistry. We expect that after treatment with HCQ tumor cells in hypoxic areas will no longer be able to survive, thus decreasing the number of viable hypoxic cells and increasing the amount of necrosis. This pilot study will serve as a proof of principle for future studies into the effect of autophagy inhibition on treatment sensitivity in breast cancer
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||20 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Autophagy Inhibition Using Hydrochloroquine in Breast Cancer Patients:a Pilot Study|
|Study Start Date :||January 2011|
|Estimated Primary Completion Date :||January 2012|
Experimental: Daily HCQ
Between tumor biopsy and surgery, during 2-3 weeks, breast cancer patients will take daily HCQ, an anti-malaria and anti-rheumatic drug that precludes tumor cells from surviving hypoxia by inhibiting the process of autophagy in these cells
800 mg per os once, and then 400 mg per day
Other Name: Plaquenil
- hypoxia markers [ Time Frame: before and after short-term pre-surgical treatment with HCQ ]differences in endogenous hypoxia markers (CA9, PAI-1, VEGF [Rademakers et al. 2008]) and autophagy (LC3b [Rouschop et al. 2010]) before and after treatment with HCQ. These parameters will be quantified by immunohistochemistry on formalin fixed paraffin embedded tissue from both pretreatment biopsy, and posttreatment surgically obtained material.
- autophagy pathway mediators [ Time Frame: before and after short-term pre-surgical treatment with HCQ ]differences in putative crucial mediators in the autophagy pathway currently under investigation, i.e. TRB3, ATF4, GRP78, LAMP3, etc.before and after short-term pre-surgical treatment with HCQ
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01292408
|Contact: P.N. Span, Md||+31 24 361 68 45||P.Span@rther.umcn.nl|
|Contact: H.W.M. van Laarhoven, Md||+31 24 361 03 email@example.com|
|University Medical Centre Nijmegen||Recruiting|
|Nijmegen, Gelderland, Netherlands, 6500 HB|
|Principal Investigator: P Span, Md|
|Sub-Investigator: H.W.M. van Laarhoven, Md|
|Principal Investigator:||P. Span, Md||University Medical Centre Nijmegen|